Register entry

ViiV Healthcare Company

Registered sites
0
Drug products
26
Live patents
59
Countries
0
Base
Unknown
Sites

Facilities

0

No registered facilities

This company holds drug listings or approvals but operates no registered establishment of its own, which is normal for an NDA holder that outsources manufacturing.

Exclusivity

Patents

59

Unexpired Orange Book patents where this company is the application holder.

ProductActive ingredientExpiry
APRETUDECABOTEGRAVIRFeb 2031
APRETUDECABOTEGRAVIRSept 2031
CABENUVA KITCABOTEGRAVIR; RILPIVIRINEJun 2027
CABENUVA KITCABOTEGRAVIR; RILPIVIRINEFeb 2031
CABENUVA KITCABOTEGRAVIR; RILPIVIRINESept 2031
CABENUVA KITCABOTEGRAVIR; RILPIVIRINENov 2031
CABENUVA KITCABOTEGRAVIR; RILPIVIRINEApr 2032
CABENUVA KITCABOTEGRAVIR; RILPIVIRINEJul 2038
CABENUVA KITCABOTEGRAVIR; RILPIVIRINEOct 2040
DOVATODOLUTEGRAVIR SODIUM; LAMIVUDINEOct 2027
DOVATODOLUTEGRAVIR SODIUM; LAMIVUDINEApr 2028
DOVATODOLUTEGRAVIR SODIUM; LAMIVUDINEDec 2029
DOVATODOLUTEGRAVIR SODIUM; LAMIVUDINEJun 2030
DOVATODOLUTEGRAVIR SODIUM; LAMIVUDINEJan 2031
JULUCADOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDEOct 2027
JULUCADOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDEApr 2028
JULUCADOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDEDec 2029
JULUCADOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDEJun 2030
JULUCADOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDEJan 2031
JULUCADOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDESept 2038
RUKOBIAFOSTEMSAVIR TROMETHAMINENov 2027
RUKOBIAFOSTEMSAVIR TROMETHAMINEJul 2029
TIVICAYDOLUTEGRAVIR SODIUMOct 2027
TIVICAYDOLUTEGRAVIR SODIUMApr 2028
TIVICAYDOLUTEGRAVIR SODIUMDec 2029
TIVICAYDOLUTEGRAVIR SODIUMJun 2030
TIVICAY PDDOLUTEGRAVIR SODIUMOct 2027
TIVICAY PDDOLUTEGRAVIR SODIUMApr 2028
TIVICAY PDDOLUTEGRAVIR SODIUMDec 2029
TIVICAY PDDOLUTEGRAVIR SODIUMJun 2030
TRIUMEQABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINEOct 2027
TRIUMEQABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINEApr 2028
TRIUMEQABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINEDec 2029
TRIUMEQABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINEJun 2030
TRIUMEQ PDABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINEOct 2027
TRIUMEQ PDABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINEApr 2028
TRIUMEQ PDABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINEDec 2029
TRIUMEQ PDABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINEJun 2030
VOCABRIACABOTEGRAVIR SODIUMFeb 2031
Catalogue

Marketed products

26

Showing 26 of 26.

BrandGeneric nameFormCategory
ApretudeCabotegravirKITNDA
ApretudeCabotegravirKITNDA
COMBIVIRlamivudine and zidovudineTABLET, FILM COATEDNDA
Cabenuvacabotegravir and rilpivirineKITNDA
Cabenuvacabotegravir and rilpivirineKITNDA
Cabenuvacabotegravir and rilpivirineKITNDA
Dovatodolutegravir sodium and lamivudineTABLET, FILM COATEDNDA
EPIVIRlamivudineTABLET, FILM COATEDNDA
EPIVIRlamivudineTABLET, FILM COATEDNDA
EPIVIRlamivudineSOLUTIONNDA
Julucadolutegravir sodium and rilpivirine hydrochlorideTABLET, FILM COATEDNDA
RETROVIRzidovudineCAPSULENDA
RETROVIRzidovudineSOLUTIONNDA
RETROVIRzidovudineINJECTION, SOLUTIONNDA
Rukobiafostemsavir tromethamineTABLET, FILM COATED, EXTENDED RELEASENDA
SELZENTRYmaravirocTABLET, FILM COATEDNDA
SELZENTRYmaravirocTABLET, FILM COATEDNDA
SELZENTRYmaravirocKITNDA
Tivicaydolutegravir sodiumTABLET, FILM COATEDNDA
Tivicaydolutegravir sodiumTABLET, FILM COATEDNDA
Tivicaydolutegravir sodiumTABLET, FILM COATEDNDA
Tivicay PDdolutegravir sodiumTABLET, FOR SUSPENSIONNDA
Triumeqabacavir sulfate, dolutegravir sodium, lamivudineTABLET, FILM COATEDNDA
Triumeq PDabacavir sulfate, dolutegravir sodium, lamivudineKITNDA
Vocabriacabotegravir sodiumTABLET, FILM COATEDNDA
ZIAGENabacavir sulfateSOLUTIONNDA
Provenance

Facility and operations data from the FDA Drug Establishments Current Registration Site. Product data from the openFDA National Drug Code Directory. Patent and exclusivity data from the FDA Orange Book. Shortage data from the FDA drug shortage database. Contact details the FDA publishes for registered establishments are deliberately not reproduced here. This entry is compiled from public records and has not been claimed by the company.